David S Hutchins1, John E Zeber2, Craig S Roberts3, Allison F Williams4, Elizabeth Manias5, Andrew M Peterson6. 1. CVS Caremark, Scottsdale, AZ, USA. Electronic address: david.hutchins@caremark.com. 2. Scott & White Healthcare, Center for Applied Health Research, Temple, TX, USA; Central Texas Veterans Health Care System, Waco, TX, USA; Texas A&M College of Medicine, Temple, TX, USA. 3. Pfizer, Inc., Collegeville, PA, USA. 4. School of Nursing and Midwifery, Monash University, Victoria, Australia. 5. Deakin University, School of Nursing and Midwifery, Victoria, Australia; Department of Medicine, Royal Melbourne Hospital, the University of Melbourne, Melbourne, Australia. 6. Mayes College of Healthcare Business and Policy, University of the Sciences, Philadelphia, PA, USA.
Abstract
BACKGROUND: Positive associations between medication adherence and beneficial outcomes primarily come from studying filling/consumption behaviors after therapy initiation. Few studies have focused on what happens before initiation, the point from prescribing to dispensing of an initial prescription. OBJECTIVE: Our objective was to provide guidance and encourage high-quality research on the relationship between beneficial outcomes and initial medication adherence (IMA), the rate initially prescribed medication is dispensed. METHODS: Using generic adherence terms, an international research panel identified IMA publications from 1966 to 2014. Their data sources were classified as to whether the primary source reflected the perspective of a prescriber, patient, or pharmacist or a combined perspective. Terminology and methodological differences were documented among core (essential elements of presented and unpresented prescribing events and claimed and unclaimed dispensing events regardless of setting), supplemental (refined for accuracy), and contextual (setting-specific) design parameters. Recommendations were made to encourage and guide future research. RESULTS: The 45 IMA studies identified used multiple terms for IMA and operationalized measurements differently. Primary data sources reflecting a prescriber's and pharmacist's perspective potentially misclassified core parameters more often with shorter/nonexistent pre- and postperiods (1-14 days) than did a combined perspective. Only a few studies addressed supplemental issues, and minimal contextual information was provided. CONCLUSIONS: General recommendations are to use IMA as the standard nomenclature, rigorously identify all data sources, and delineate all design parameters. Specific methodological recommendations include providing convincing evidence that initial prescribing and dispensing events are identified, supplemental parameters incorporating perspective and substitution biases are addressed, and contextual parameters are included.
BACKGROUND: Positive associations between medication adherence and beneficial outcomes primarily come from studying filling/consumption behaviors after therapy initiation. Few studies have focused on what happens before initiation, the point from prescribing to dispensing of an initial prescription. OBJECTIVE: Our objective was to provide guidance and encourage high-quality research on the relationship between beneficial outcomes and initial medication adherence (IMA), the rate initially prescribed medication is dispensed. METHODS: Using generic adherence terms, an international research panel identified IMA publications from 1966 to 2014. Their data sources were classified as to whether the primary source reflected the perspective of a prescriber, patient, or pharmacist or a combined perspective. Terminology and methodological differences were documented among core (essential elements of presented and unpresented prescribing events and claimed and unclaimed dispensing events regardless of setting), supplemental (refined for accuracy), and contextual (setting-specific) design parameters. Recommendations were made to encourage and guide future research. RESULTS: The 45 IMA studies identified used multiple terms for IMA and operationalized measurements differently. Primary data sources reflecting a prescriber's and pharmacist's perspective potentially misclassified core parameters more often with shorter/nonexistent pre- and postperiods (1-14 days) than did a combined perspective. Only a few studies addressed supplemental issues, and minimal contextual information was provided. CONCLUSIONS: General recommendations are to use IMA as the standard nomenclature, rigorously identify all data sources, and delineate all design parameters. Specific methodological recommendations include providing convincing evidence that initial prescribing and dispensing events are identified, supplemental parameters incorporating perspective and substitution biases are addressed, and contextual parameters are included.
Authors: Janice B Schwartz; Kenneth E Schmader; Joseph T Hanlon; Darrell R Abernethy; Shelly Gray; Jacqueline Dunbar-Jacob; Holly M Holmes; Michael D Murray; Robert Roberts; Michael Joyner; Josh Peterson; David Lindeman; Ming Tai-Seale; Laura Downey; Michael W Rich Journal: J Am Geriatr Soc Date: 2018-12-07 Impact factor: 5.562
Authors: Michael J Stirratt; Jeffrey R Curtis; Maria I Danila; Richard Hansen; Michael J Miller; C Ann Gakumo Journal: J Gen Intern Med Date: 2018-02 Impact factor: 5.128
Authors: Ignacio Aznar-Lou; Ana Fernández; Montserrat Gil-Girbau; Marta Fajó-Pascual; Patricia Moreno-Peral; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Albert Sánchez-Niubó; María Antonia March-Pujol; Anna Maria Jové; Maria Rubio-Valera Journal: Br J Clin Pharmacol Date: 2017-02-24 Impact factor: 4.335
Authors: Alba Sánchez-Viñas; Carmen Corral-Partearroyo; Montserrat Gil-Girbau; M Teresa Peñarrubia-María; Carmen Gallardo-González; María-Del-Carmen Olmos-Palenzuela; Ignacio Aznar-Lou; Antoni Serrano-Blanco; Maria Rubio-Valera Journal: BMC Prim Care Date: 2022-07-05
Authors: Ignacio Aznar-Lou; Ana Fernández; Montserrat Gil-Girbau; Ramón Sabés-Figuera; Marta Fajó-Pascual; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Patricia Moreno-Peral; Albert Sánchez-Niubó; Marian March-Pujol; Maria Rubio-Valera Journal: Br J Gen Pract Date: 2017-07-31 Impact factor: 5.386
Authors: Sue P Heiney; Samantha Truman; Oluwole A Babatunde; Tisha M Felder; Jan M Eberth; Elizabeth Crouch; Karen E Wickersham; Swann Arp Adams Journal: Am J Clin Oncol Date: 2020-07 Impact factor: 2.787
Authors: Enrica Menditto; Caitriona Cahir; Sara Malo; Isabel Aguilar-Palacio; Marta Almada; Elisio Costa; Anna Giardini; María Gil Peinado; Mireia Massot Mesquida; Sara Mucherino; Valentina Orlando; Carlos Luis Parra-Calderón; Enrique Pepiol Salom; Przemyslaw Kardas; Bernard Vrijens Journal: Int J Environ Res Public Health Date: 2021-05-03 Impact factor: 3.390